Silicone breast implants: Immunotoxic and epidemiologic issues

Steven H. Yoshida, Shanna Swan, Suzanne S Teuber, M. Eric Gershwin

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Silicone gel implants for breast augmentation and reconstruction have been in use since 1962. Significant local complications include capsular contracture, rupture, gel "bleed", and spread of the implant material to regional lymph nodes (1-7) as well as histologie findings of foreign body granulomas in the capsular tissue and in lymph nodes (7-9). Through magnetic resonance spectroscopy and atomic emission spectroscopy, silicon compounds were found in the blood of some women with silicone breast implants; silicone and silica have also been found in liver (10). Wellpublicized case reports have raised significant concerns regarding an association between implants and systemic disease. However, despite the availability of silicone implants for over 30 years, controlled epidemiological studies were not carried out until 1992. Currently available epidemiologic data are extremely limited. In part, because the majority of implants were used after 1981, the incidence of long-term problems is not yet known. In 1992, due to the unavailability of studies demonstrating the safety of implants, the U.S. Food and Drug Administration advised that silicone breast implants should be used only in reconstructive surgery and as part of clinical trials (11). This decision spurred a wave of research on the bioreactivity of silicone and clinical observations of patients with implants. Herein, we review the adverse immune effects following contact with silicone as well as the epidemiologic data available.

Original languageEnglish (US)
Pages (from-to)1299-1310
Number of pages12
JournalLife Sciences
Volume56
Issue number16
DOIs
StatePublished - Mar 10 1995

Fingerprint

Breast Implants
Silicones
Reconstructive Surgical Procedures
Silicon Compounds
Lymph Nodes
Foreign-Body Granuloma
Silicone Gels
Magnetic resonance spectroscopy
Atomic emission spectroscopy
Mammaplasty
Contracture
United States Food and Drug Administration
Silicon Dioxide
Liver
Surgery
Epidemiologic Studies
Rupture
Spectrum Analysis
Blood
Magnetic Resonance Spectroscopy

Keywords

  • autoimmunity
  • epidemiology
  • immunotoxicology
  • silicone breast implants

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology

Cite this

Silicone breast implants : Immunotoxic and epidemiologic issues. / Yoshida, Steven H.; Swan, Shanna; Teuber, Suzanne S; Gershwin, M. Eric.

In: Life Sciences, Vol. 56, No. 16, 10.03.1995, p. 1299-1310.

Research output: Contribution to journalArticle

Yoshida, Steven H. ; Swan, Shanna ; Teuber, Suzanne S ; Gershwin, M. Eric. / Silicone breast implants : Immunotoxic and epidemiologic issues. In: Life Sciences. 1995 ; Vol. 56, No. 16. pp. 1299-1310.
@article{53e7dd8a56c7487db57182964e42ec1a,
title = "Silicone breast implants: Immunotoxic and epidemiologic issues",
abstract = "Silicone gel implants for breast augmentation and reconstruction have been in use since 1962. Significant local complications include capsular contracture, rupture, gel {"}bleed{"}, and spread of the implant material to regional lymph nodes (1-7) as well as histologie findings of foreign body granulomas in the capsular tissue and in lymph nodes (7-9). Through magnetic resonance spectroscopy and atomic emission spectroscopy, silicon compounds were found in the blood of some women with silicone breast implants; silicone and silica have also been found in liver (10). Wellpublicized case reports have raised significant concerns regarding an association between implants and systemic disease. However, despite the availability of silicone implants for over 30 years, controlled epidemiological studies were not carried out until 1992. Currently available epidemiologic data are extremely limited. In part, because the majority of implants were used after 1981, the incidence of long-term problems is not yet known. In 1992, due to the unavailability of studies demonstrating the safety of implants, the U.S. Food and Drug Administration advised that silicone breast implants should be used only in reconstructive surgery and as part of clinical trials (11). This decision spurred a wave of research on the bioreactivity of silicone and clinical observations of patients with implants. Herein, we review the adverse immune effects following contact with silicone as well as the epidemiologic data available.",
keywords = "autoimmunity, epidemiology, immunotoxicology, silicone breast implants",
author = "Yoshida, {Steven H.} and Shanna Swan and Teuber, {Suzanne S} and Gershwin, {M. Eric}",
year = "1995",
month = "3",
day = "10",
doi = "10.1016/0024-3205(95)00081-X",
language = "English (US)",
volume = "56",
pages = "1299--1310",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "16",

}

TY - JOUR

T1 - Silicone breast implants

T2 - Immunotoxic and epidemiologic issues

AU - Yoshida, Steven H.

AU - Swan, Shanna

AU - Teuber, Suzanne S

AU - Gershwin, M. Eric

PY - 1995/3/10

Y1 - 1995/3/10

N2 - Silicone gel implants for breast augmentation and reconstruction have been in use since 1962. Significant local complications include capsular contracture, rupture, gel "bleed", and spread of the implant material to regional lymph nodes (1-7) as well as histologie findings of foreign body granulomas in the capsular tissue and in lymph nodes (7-9). Through magnetic resonance spectroscopy and atomic emission spectroscopy, silicon compounds were found in the blood of some women with silicone breast implants; silicone and silica have also been found in liver (10). Wellpublicized case reports have raised significant concerns regarding an association between implants and systemic disease. However, despite the availability of silicone implants for over 30 years, controlled epidemiological studies were not carried out until 1992. Currently available epidemiologic data are extremely limited. In part, because the majority of implants were used after 1981, the incidence of long-term problems is not yet known. In 1992, due to the unavailability of studies demonstrating the safety of implants, the U.S. Food and Drug Administration advised that silicone breast implants should be used only in reconstructive surgery and as part of clinical trials (11). This decision spurred a wave of research on the bioreactivity of silicone and clinical observations of patients with implants. Herein, we review the adverse immune effects following contact with silicone as well as the epidemiologic data available.

AB - Silicone gel implants for breast augmentation and reconstruction have been in use since 1962. Significant local complications include capsular contracture, rupture, gel "bleed", and spread of the implant material to regional lymph nodes (1-7) as well as histologie findings of foreign body granulomas in the capsular tissue and in lymph nodes (7-9). Through magnetic resonance spectroscopy and atomic emission spectroscopy, silicon compounds were found in the blood of some women with silicone breast implants; silicone and silica have also been found in liver (10). Wellpublicized case reports have raised significant concerns regarding an association between implants and systemic disease. However, despite the availability of silicone implants for over 30 years, controlled epidemiological studies were not carried out until 1992. Currently available epidemiologic data are extremely limited. In part, because the majority of implants were used after 1981, the incidence of long-term problems is not yet known. In 1992, due to the unavailability of studies demonstrating the safety of implants, the U.S. Food and Drug Administration advised that silicone breast implants should be used only in reconstructive surgery and as part of clinical trials (11). This decision spurred a wave of research on the bioreactivity of silicone and clinical observations of patients with implants. Herein, we review the adverse immune effects following contact with silicone as well as the epidemiologic data available.

KW - autoimmunity

KW - epidemiology

KW - immunotoxicology

KW - silicone breast implants

UR - http://www.scopus.com/inward/record.url?scp=0028899465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028899465&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(95)00081-X

DO - 10.1016/0024-3205(95)00081-X

M3 - Article

C2 - 8614251

AN - SCOPUS:0028899465

VL - 56

SP - 1299

EP - 1310

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 16

ER -